⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1372426 | 0.97 | ALDH1A1 (0.41) | — | |
| SCHEMBL1178607 | 0.76 | — | — | |
| SCHEMBL29993479 | 0.74 | MAPK1 (0.47) | — | |
| SCHEMBL22824510 | 0.72 | TDP1 (0.41) | — | |
| SCHEMBL14410070 | 0.70 | CCNC (0.37) | — | |
| SCHEMBL3744025 | 0.69 | — | — | |
| SCHEMBL9022352 | 0.67 | TBXAS1 (0.53) | — | |
| SCHEMBL18606404 | 0.66 | LMNA (0.47) | — | |
| SCHEMBL16411193 | 0.66 | GRIN2B (0.37) | — | |
| SCHEMBL1073206 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380560-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Contineum Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118043041-A | LPAR1 antagonists and uses thereof | 康蒂内乌姆医疗公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230087342-A1 | AZEPANE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| WO-2023014908-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023014908-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022210479-A1 | USE OF AZEPANE DERIVATIVE FOR TREATMENT, AMELIORATION OR PREVENTION OF κ-OPIOID RECEPTOR-RELATED DISEASES | 日本ケミファ株式会社 | 2022-10-06 | — | — | WO | disclosed |
| EP-4039331-A1 | AZEPAN DERIVATIVE | Nippon Chemiphar Co., Ltd. (JP) | 2022-08-10 | — | — | EP | disclosed |
| CN-114761082-A | Azepane derivatives | 日本化学药品株式会社 | 2022-07-15 | — | — | CN | disclosed |
| WO-2009123870-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009124166-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
| WO-2009124167-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| EP-1885713-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| US-20070284258-A1 | Method For Silver Plating | DAIWA FINE CHEMICALS CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| WO-2006123242-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |